-+ 0.00%
-+ 0.00%
-+ 0.00%

Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results

Benzinga·10/29/2026 11:21:01
Listen to the news

IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027

KRAS Wild-Type Subgroup Achieved 43.3% ORR Versus 11.4% in KRAS-Mutant Disease and Novel Biomarker-Enriched Subgroup Achieved 59.1% ORR

POSITILITY, a First-In-Class Biomarker-Enriched Study with Registrational Intent, to Begin Enrollment in November 2026